drugset / Trial / NCT00349128

Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

NCT00349128

Phase 2/3 Completed 382 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.

Timeline

Start
2004-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule
Background Metformin Small molecule

Indications